blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1736539

EP1736539 - Attenuated SARS-CoV vaccines [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  22.02.2008
Database last updated on 22.08.2024
Most recent event   Tooltip22.02.2008Application deemed to be withdrawnpublished on 26.03.2008  [2008/13]
Applicant(s)For all designated states
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
C/ Serrano 117
28006 Madrid / ES
[N/P]
Former [2006/52]For all designated states
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Serrano, 117
28006 Madrid / ES
Inventor(s)01 / Álvarez Gómez, Enrique
C/ Santiago de Compostela, 88 8[deg] G
28035 Madrid / ES
02 / López de Diego, Marta
C/ Castilla la Mancha, n[deg] 146
28700 San Sebastián de los Reyes, Madrid / ES
03 / Enjuanes Sanches, Luis
Camino Nuevo, 113 La Moraleja
28109 Madrid / ES
04 / Almazán Toral, Fernando
C/ La del Soto del Parral 1, 1A
28041 Madrid / ES
 [2006/52]
Representative(s)Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstrasse 4
22607 Hamburg / DE
[N/P]
Former [2006/52]UEXKÜLL & STOLBERG
Patentanwälte Beselerstrasse 4
22607 Hamburg / DE
Application number, filing date05013727.224.06.2005
[2006/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1736539
Date:27.12.2006
Language:EN
[2006/52]
Search report(s)(Supplementary) European search report - dispatched on:EP31.03.2006
ClassificationIPC:C12N7/04, A61K39/215, A61P11/00
[2006/52]
CPC:
A61K39/215 (EP); A61K39/12 (EP); A61P11/00 (EP);
C07K14/005 (EP); C12N7/00 (EP); A61K2039/5254 (EP);
A61K2039/53 (EP); C12N2770/20022 (EP); C12N2770/20034 (EP);
C12N2770/20061 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/52]
TitleGerman:Abgeschwächte SARS-CoV Impfstoffe[2006/52]
English:Attenuated SARS-CoV vaccines[2006/52]
French:Vaccins comprenant le SARS-CoV atténué[2006/52]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure28.06.2007Application deemed to be withdrawn, date of legal effect  [2008/13]
06.11.2007Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2008/13]
Fees paidRenewal fee
14.06.2007Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2004085633  (UNIV HONG KONG [CN]) [Y] 1-3,6-23 * pages 20-24; sequence 15 *;
 [Y]WO2004091524  (ACAMBIS INC [US], et al) [Y] 1-3,6-23 * the whole document *;
 [Y]  - HUANG Y ET AL, "GENERATION OF SYNTHETIC SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS PSEUDOPARTICLES: IMPLICATIONS FOR ASSEMBLY AND VACCINE PRODUCTION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (200411), vol. 78, no. 22, ISSN 0022-538X, pages 12557 - 12565, XP009046697 [Y] 1-3,6-23 * the whole document *

DOI:   http://dx.doi.org/10.1128/JVI.78.22.12557-12565.2004
 [Y]  - KUO LILI ET AL, "The small envelope protein E is not essential for murine coronavirus replication.", JOURNAL OF VIROLOGY, (200304), vol. 77, no. 8, ISSN 0022-538X, pages 4597 - 4608, XP002359410 [Y] 1-3,6-23 * the whole document *

DOI:   http://dx.doi.org/10.1128/JVI.77.8.4597-4608.2003
 [Y]  - HE Y ET AL, "Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20041210), vol. 325, no. 2, ISSN 0006-291X, pages 445 - 452, XP004626814 [Y] 1-3,6-23 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2004.10.052
 [Y]  - ZHANG C-H ET AL, "Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20050502), vol. 23, no. 24, ISSN 0264-410X, pages 3196 - 3201, XP004851707 [Y] 1-3,6-23 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2004.11.073
    [ ] - "hSARS virus genome, SEQ ID 15.", Geneseq, (20041230), Database accession no. ADT36557, URL: EBI
    [ ] - "SARS coronavirus Urbani strain complete genome.", Geneseq, (20050113), Database accession no. ADT08491, URL: EBI
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.